[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spasticity-as-sequela-of-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spasticity-as-sequela-of-stroke":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,76,109,135,162],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100589736","cryoneurolysis-for-spasticity-treatment-long-term-clinical-outcomes-and-mechanisms-in-the-central-nervous-system-100589736",false,"NCT06958289","Cryoneurolysis for Spasticity Treatment: Long-term Clinical Outcomes and Mechanisms in the Central Nervous System","Cryoneurolysis for Spasticity Treatment: Quantifying Long-term Clinical Outcomes and Exploring Mechanisms Within the Central Nervous System","Inclusion Criteria:\n\n* have increased range of motion or reduced spasticity with diagnostic nerve block,\n* have no undesired loss of function with a diagnostic nerve block,\n* score 2 or higher in the Modified Ashworth scale,\n* have at least flickers of movement in the upper extremity,\n* have not received botulinum-A neurotoxin within the past 3 months,\n* if on anti-spastic medication, maintaining anti-spastic medications on a stable schedule over the course of the follow up period, and\n* they can understand and follow instructions in English.\n\nExclusion Criteria:\n\n* have contraindications to TMS (i.e., history of seizure, pregnancy) or 3T MRI (i.e., certain metallic implants),\n\n  * are unable to provide informed consent (i.e., severe cognitive impairment),\n  * receive any toxin injections for spasticity (Botulinum-A Toxin or equivalent) within 3 months of initial baseline assessments or at any time over the course of the follow-up period.\n  * Have previously undergone any nerve-specific interventions (phenol neurolysis, radio-frequency ablation, or cryoneurolysis) for spasticity on a nerve that will be targeted for this study.","ALL","18 Years",{"count":19,"type":20},25,"ESTIMATED","INTERVENTIONAL",[23],"NA","Spasticity can make regular daily activities difficult or impossible. Cryoneurolysis is a new technique to treat spasticity that is currently being tested. For this technique, a needle is inserted alongside a nerve implicated in spasticity. The needle then freezes and causes the nerve to break down. The nerve breaking down seems to provide relief for spasticity. The investigators are interested in testing the long-term effects of cryoneurolysis on the function of the brain over six months after treatment. The investigators are testing the brain's function using transcranial magnetic stimulation (TMS) which involves a magnet activating specific parts of the brain that cause muscles to fire; magnetic resonance imaging (MRI) which uses to examine brain structure; functional near-infrared spectroscopy (fNIRS) to examine brain function. The investigators believe that there will be a change in these measures that are related to the long-lasting effects of cryoneurolysis. Cryoneurolysis is not a part of standard care after stroke but is approved in Canada for patients. It has been used extensively in the past for treating pain. TMS is a way of studying how the brain sends signals to muscles to make movement. During these sessions, a researcher will use a magnet to turn on specific neurons in the brain that will cause muscles to contract. The investigators can study the way eyes and muscles respond to better understand how the brain is sending information about moving the body to the muscles. FNIRS is a new way of studying how the brain works. During these sessions, a researcher will fit the participant with a cap that has several lights on it. The light travels through hair, scalp, and skull where it interacts with blood in the brain. By studying the changes in the colour of the blood in the brain, researchers can understand which parts of the brain are active during specific tasks. Magnetic Resonance Imaging (MRI) involves a powerful magnet that takes very detailed pictures of the brain. These images help the investigators to understand how a stroke is related to spasticity. Also, these images are helpful to make the stimulation with TMS more accurate. Study participation will require five visits to the Parkwood Institute Main Building and one visit to St. Joseph's Hospital. The entire study will take place over roughly six months. The investigators are recruiting 25 people with stroke who are eligible for cryoneurolysis to participate in the study.",[26],"Spasticity as Sequela of Stroke",[28,29,30,31],"NIRS","TMS","cryoneurolysis","fNIRS","RECRUITING","2026-04-15",{"date":35,"type":36},"2026-04-21","ACTUAL",{"date":38,"type":36},"2025-08-01",{"date":40,"type":20},"2028-05-01",{"name":42,"class":43},"Sue Peters","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100626787","phase-4-phenol-and-botulinum-toxin-vs-botulinum-toxin-alone-for-post-stroke-upper-limb-spasticity-100626787","NCT07440173","Phenol and Botulinum Toxin vs Botulinum Toxin Alone for Post-Stroke Upper-Limb Spasticity","Combined Phenol and Botulinum Toxin vs Botulinum Toxin Alone for Upper-Limb Spasticity After Stroke: A Randomized Trial","* Inclusion criteria :\n\n  * Adults aged 18 to 70 years.\n  * Diagnosis: Documented Ischemic or Hemorrhagic stroke (with a duration of at least 6 months post-stroke to ensure a chronic, stable phase).\n  * Spasticity Severity: A score of 2 on the Modified Ashworth Scale (MAS) in at least one proximal muscle group (Shoulder adductors or Elbow flexors).\n  * Functional Status: Evidence of upper limb motor impairment but with enough stability to participate in follow-up.\n  * Cognitive Ability: Ability to understand and follow instructions (Mini-Mental State Examination score typically 24) to ensure cooperation during TMS and functional testing.\n  * Consent: Signed informed consent provided by the patient or a legal guardian.\n* Exclusion Criteria :\n\n  * Fixed Contractures: Any permanent joint deformity or fixed contracture in the target limb that would prevent range of motion improvement.\n  * Prior Treatment: Received Botulinum Toxin or phenol injections in the affected limb within the last 6 months.\n  * TMS Contraindications: History of seizures.\n  * Presence of metallic implants in the head or neck (e.g., clips, shunts).\n  * Cardiac pacemakers or implanted medication pumps.\n  * Local Factors:Skin infection or inflammation at the planned injection sites.\n  * Medical Co-morbidities: Significant peripheral nerve disease (other than the stroke-related upper motor neuron lesion) or severe psychiatric disorders.\n  * Phenol Sensitivity: Known hypersensitivity to phenol or its derivatives.","70 Years",{"count":54,"type":20},60,[56],"PHASE4","This study aims to evaluate the efficacy of a combined treatment approach for post-stroke upper limb spasticity using phenol neurolysis and botulinum toxin (BoNT). Spasticity is a common post-stroke complication that leads to muscle stiffness and significantly hinders functional recovery. While botulinum toxin is the standard treatment, its high cost often limits its application, particularly for large proximal muscles.\n\nThe researchers will compare two treatment strategies in 60 adult stroke survivors:\n\nGroup A (Combined Therapy): Patients will receive ultrasound-guided phenol neurolysis for the proximal nerves (pectoralis and musculocutaneous nerves) and botulinum toxin for the distal forearm flexors.\n\nGroup B (Standard Care): Patients will receive botulinum toxin alone for all affected muscles in the upper limb.\n\nAll procedures will be performed under ultrasound guidance to ensure anatomical precision. The study will also utilize Transcranial Magnetic Stimulation (TMS) to assess changes in cortical excitability (RMT, MEPs, and cortical silent period). The primary goal is to determine if this combined approach effectively reduces muscle stiffness (measured by the Modified Ashworth Scale) while potentially reducing the total dose of botulinum toxin required per patient.",[26],[60,61,62,63,64,65],"Phenol Neurolysis","Botulinum Toxin Type A","Transcranial Magnetic Stimulation (TMS)","Cortical Excitability","Upper Limb Rehabilitation","Ultrasound-Guided Injection","NOT_YET_RECRUITING","2026-02-25",{"date":69,"type":36},"2026-02-27",{"date":71,"type":20},"2026-05-01",{"date":73,"type":20},"2027-07-15",{"name":75,"class":43},"Assiut University",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":87,"conditions":88,"keywords":94,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100623939","improving-step-in-stroke-patients-100623939","NCT07403149","Improving STEP in Stroke Patients","Evaluating the Improvement of Stepping Quality by Using Adapted Shoes","I-STEP","Inclusion Criteria:\n\n1. Aged over 18 years\n2. With health insurance card \" carte vitale \" (being affiliated to the French security system) on \"ALD\" (Affection de longue durée) meaning reimbursement at a 100% rate\n3. With a past history of stroke (ischemic or hemorrhagic) with a Rankin score 2 to 4, once stabilized (no more improvement), at least 6 months after stroke onset\n4. Spasticity on one side of the body, with spastic walking, with tip-toeing gait, resulting in a \"mowing wheats-like\" movement of the leg as described in the French literature\n5. Patient had full medical examination prior to this research\n6. Informed and written consent of the participant.\n\nExclusion Criteria:\n\n1. Impossible to walk (wheel chair or bedridden)\n2. Diabetic foot\n3. Unhealed and\u002For painful foot injury\n4. Acquired deformity of a foot (osteophytosis, parrot beak on metatarso-phalangeal joint of the first ray, a bunion or hallux valgus, or hallux rigidus or stiffness of the big toe)\n5. Intercurrent disease that may interfere with the evaluation of the primary outcome (Parkinson's disease, peripheral neuropathy, Little's disease, significant hip or knee injury)",{"count":85,"type":20},58,[23],"Stroke is the leading cause of acquired disability in adults. Stroke causes death in 10% of patients, disability and functional handicap in 60% of cases. Sequelea of hemiplegia include spasticity resulting in great difficulty and slowness in walking, gait instability, increasing the risk of falls.\n\nDeambulation may need help (cane, crutch, tripod cane, walker). Lower limb spasticity includes hypertonia of extensors (gluteus maximus, quadriceps, posterior gastrocnemius) resulting in equinovarus. A neurology deficit may be present on ipsilateral lower limb flexors. Hence the patient walks with rubbing of the tip of the foot (tip-toeing gait), resulting in a \"mowing wheatslike\" movement of the leg as described in the French literature. Walking is then slowed down, unstable, with increased risk of falls.\n\nIn post stroke, during the period of rehabilitation and beyond, it is advisable to wear sports shoes although custom-made shoes improve walking and are reimbursed by the French social security system after prior agreement. Most of patients only wear conventional shoes.",[89,90,91,26,92,93],"Stroke","Hemiplegia Following Ischemic Stroke","Disability Physical","Gluteus Maximus Muscle Atrophy","Equinovarus Foot",[89,95,96,97,98,99],"Hemiplegia","equinovarus","orthopedic shoes","REMARCHE® shoes","Walking performance","2026-02-04",{"date":102,"type":36},"2026-02-11",{"date":104,"type":20},"2026-03-01",{"date":106,"type":20},"2026-04-01",{"name":108,"class":43},"Assistance Publique - Hôpitaux de Paris",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":117,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100521487","radiosurgery-treatment-for-spasticity-associated-with-stroke-sci--cerebral-palsy-100521487","NCT06070233","Radiosurgery Treatment for Spasticity Associated With Stroke, SCI & Cerebral Palsy","A Randomized, Sham Controlled Trial of Dorsal Root Rhizotomy Stereotactic Radiosurgery Versus Standard of Care for Spasticity Associated With Stroke, Spinal Cord Injury & Cerebral Palsy","SPASM","Inclusion Criteria:\n\n* Chronic spasticity refractory to medical management or in a patient who cannot receive appropriate medical management mediated by one or more spinal nerve roots\n* Age \\> 16 (if under 18, patients parents must sign consent).\n\nExclusion Criteria:\n\n* Inability to lie supine for simulation \\& treatment\n* Inability to visualize the target nerve on either CT or MRI imaging\n* Patients with confirmed pregnancy (all women of child-bearing age with intact uterus \\& ovaries will be required to undergo a pregnancy test prior to simulation)","16 Years",{"count":119,"type":20},22,[23],"A scientific study is being done to test a special treatment for people who have spasticity or tight muscles. This treatment is called \"stereotactic radiosurgery dorsal rhizotomy.\" It uses very accurate beams of radiation to target certain nerves in the back to help loosen up the muscles. In this study, people are put into two groups by chance: one group gets the real treatment, and the other group gets a \"fake\" treatment that doesn't do anything. This fake treatment is called a \"sham.\" Doing this helps make sure the study is fair and the results are true. After the people in the study get their treatment, the researchers will watch and see how they do. They will check if their muscles are less stiff and if they have any side effects. By looking at the results from both groups, the researchers can find out if the special treatment really helps people with spasticity. Patients who got the \"fake\" treatment will be eligible to receive the \"real\" treatment after 6 months.",[26,123,124],"Spastic Cerebral Palsy","Spasticity, Muscle","2025-12-18",{"date":127,"type":36},"2025-12-19",{"date":129,"type":36},"2023-10-12",{"date":131,"type":20},"2026-12-31",{"name":133,"class":43},"Ohio State University",2,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":21,"phases":143,"briefSummary":144,"conditions":145,"keywords":146,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":44},"100517470","effects-of-dry-needling-on-electromyographic-activity-and-ultrasonographic-characteristics-in-post-stroke-spasticity-100517470","NCT06017960","Effects of Dry Needling on Electromyographic Activity and Ultrasonographic Characteristics in Post-Stroke Spasticity","Inclusion Criteria:\n\n* be over 18 years old\n* understand and voluntarily sign informed consent before performing the intervention\n* have a medical diagnosis of ischemic or hemorrhagic stroke\n* have a grade between 1-3 according to the modified Ashworth scale (MAS) on the triceps sural\n* able to walk independently to perform gait test\n\nExclusion Criteria:\n\n* recurrent stroke\n* who have received previous treatments of botulinum toxin type A in the last 3 months\n* who have received treatments with dry needling in the last month\n* severe cognitive deficits\n* fear of needles\n* metal allergy.",{"count":142,"type":20},28,[23],"Stroke is a global health problem, with an incidence in Europe of 147\u002F100,000 people per year. It is estimated that 43% of them present spasticity throughout the first year, causing disability, hindering mobility and functionality, which can generate comorbidity problems, which in turn hinders its improvement over time.\n\nRecently, high quality studies have conclude that there is a moderate level of evidence with large effect size in reducing spasticity with dry needling, as well as being cost-effective in stroke patients in both the subacute and chronic phases. However, due to the limitation of manual evaluations of spasticity, and it is necessary to look for measurement alternatives that complement it, such as the analysis of the electromyographic activity and the muscular structure measured with ultrasound. These data could provide objective, useful and complementary information to clinical assessments to be more specific and effective in the treatment of stroke patients.\n\nThis randomized controlled trial aim to analyse the effect of dry needling in this parameters in patients with stroke and spasticity, as well as correlated with gait variables. Each participant will be randomly assigned to the dry needling group or to the sham dry needling group, where participants receive a total of 4 sessions of ultrasound-guided dry needling or sham ultrasound-guided dry needling in the gastrocnemius medialis over 4 weeks, one per week. Measures of spasticity, electromyographic activity and muscle structure via ultrasound will made at baseline (T0) and immediate after each intervention (T1,T2,T3,T4). Gait variables will be made at baseline and after the last intervention (T0 and T4).",[26],[147,148,149,150,151,152],"Dry needling","Spasticity","Hypertonia","Surface electromyography","Diagnostic ultrasound","Gait","2025-11-27",{"date":155,"type":36},"2025-12-04",{"date":157,"type":36},"2023-09-15",{"date":159,"type":20},"2026-09-15",{"name":161,"class":43},"Universidad de Zaragoza",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":172,"phases":4,"briefSummary":173,"conditions":174,"keywords":178,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":44},"100453050","prognosis-and-diagnosis-of-spasticity-in-acute-post-stroke-patients-100453050","NCT05179473","Prognosis and Diagnosis of Spasticity in Acute-post Stroke Patients","Changing Practice: Prognosis and Diagnosis of Spasticity in Acute-post Stroke Patients: a Pilot Study","Inclusion Criteria:\n\n* Acute stroke in Middle Cerebral Artery area resulting in hemiparesis.\n* Hemorrhagic or ischemic\n* Medically stable\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Severe cognitive disorders\n* Ataxia","85 Years",{"count":171,"type":20},12,"OBSERVATIONAL","Spasticity, or greater muscle resistance, is a major disabling condition following stroke. Recovery of lost motor function in patients with stroke may be affected by spasticity, which most commonly develops in elbow and ankle muscles. However, despite its clinical relevance, the natural development of spasticity over the first 3 months after stroke is not clearly understood. Indeed, common clinical measures of spasticity such as the Modified Ashworth Scale (MAS) do not take into account the neurophysiological origin of spasticity and lack reliability and objectivity.\n\nThe objective of this study is to examine the natural history of the development of spasticity among patients with stroke over the first 3 months using a new neurophysiological measure (TSRT, the tonic stretch reflex threshold angle) and its velocity sensitivity (mu) in comparison to MAS and other common clinical tests. In addition, detailed brain imaging will be used to understand the relationship between damage to brain regions relevant to the development of spasticity and TSRT\u002Fmu values.\n\nIt is hypothesized that 1) TSRT\u002Fmu will indicate the presence of spasticity earlier than MAS\u002Fclinical tests; 2) TSRT\u002Fmu measures will be more closely related to motor impairments and activity limitations than MAS; 3) the lesion severity (identified by imaging) will be related to the change in TSRT\u002Fmu values.\n\nOutcomes will be measured in a pilot cohort of 12 patients hospitalized for first-ever stroke. Measurements will be taken at the bedside within the 1st week of the patient's admission and will be done once per week for 12 weeks with a follow-up at week 16. Brain Imaging will be done around the 6th week post-stroke.",[175,176,177,26],"Stroke, Acute","Stroke, Ischemic","Stroke Hemorrhagic",[179,180,181,182,183,184,185],"stroke","spasticity","imaging","prognosis","diagnosis","upper limb","lower limb","2025-05-30",{"date":188,"type":36},"2025-06-04",{"date":190,"type":36},"2021-06-17",{"date":192,"type":20},"2025-12-30",{"name":194,"class":43},"McGill University"]